Antibodies have been used for more than 100 years in the therapy of infectious diseases,
but a new generation of highly potent and/or broadly cross-reactive human monoclonal …

Antibody-based therapies are currently undergoing a renaissance. After being developed
and then largely abandoned in the twentieth century, many antibody preparations are now in …

Antibodies are considered as an excellent foundation to neutralize pathogens and as highly
specific therapeutic agents. Antibodies are generated in response to a vaccine but little use …

Monoclonal antibodies (mAbs) are increasingly being considered as agents to fight severe
viral diseases. So far, they have essentially been selected and used on the basis of their …

Antibody preparations have a long history of providing protection from infectious diseases.
Although antibodies remain the only natural host-derived defense mechanism capable of …

Neutralizing antibodies play an essential part in antiviral immunity and are instrumental in
preventing or modulating viral diseases. Polyclonal antibody preparations are increasingly …

Antibodies can prevent infectious diseases by providing passive immune protection. Here
we review successful clinical trials of passive immunization and consider some of the unique …

Monoclonal antibodies (mAbs) have long provided powerful research tools for virologists to
understand the mechanisms of virus entry into host cells and of antiviral immunity. Even so …

In recent years antibody-based therapies have returned as first-line therapy for a variety of
diverse conditions that include viral infections, inflammatory disorders, and certain …

The natural human antibody response is a rich source of highly specific, neutralizing and
self-tolerant therapeutic reagents. Recent advances have been made in isolating and …